BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Also on February 6, 2018, the Board appointed John Canepa, who is currently a member of the Audit Committee of the Board (the “Audit Committee”), to serve as the Chairman of the Audit Committee to fill the vacancy created as a result of Mr. Kennedy’s resignation.
|Item 9.01.||Financial Statements and Exhibits.|
Biostage, Inc. ExhibitEX-99.1 2 tv485182_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Biostage,…To view the full exhibit click
About BIOSTAGE, INC. (NASDAQ:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.